MEKANISTIC THERAPEUTICS
MEKANISTIC THERAPEUTICS
Industry:
Biotechnology Life Science Medical Product Research
Address:
Ann Arbor, Michigan, United States
Country:
United States
Website Url:
http://www.mekanistictherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
734-998-8327
Email Addresses:
[email protected]
Total Funding:
30 M USD
Technology used in webpage:
Google Apps For Business Amazon Route 53 Squarespace Hosted
Official Site Inspections
http://www.mekanistictherapeutics.com
- Host name: 198.49.23.145
- IP address: 198.49.23.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Mekanistic Therapeutics"
MEKanistic Therapeutics
Developing a novel category of precision medicines that offer targeted and long-lasting benefits for cancer patients. Harnessing the potential of well-established biological targets, our portfolio …See details»
About - MEKanistic Therapeutics
We choose to adopt fresh perspectives, concentrating on understanding why cancer therapies falter over time rather than pursue incremental treatment improvements. In this pursuit, we are …See details»
Mekanistic Therapeutics - Crunchbase Company Profile …
Mekanistic is a biotechnology company that is redefining oncology. They offer a novel class of selective kinase inhibitors that are rationally designed to target EGFR and PI3K with a single molecule. They use computational tools and …See details»
Mekanistic Therapeutics - Overview, News & Similar companies
Who is Mekanistic Therapeutics. Mekanistic Therapeutics, a startup company focused on the development of cancer therapeutics, will soon move into the U-M Tech Transfer Venture Acc …See details»
MEKanistic Therapeutics - LinkedIn
Redefining precision oncology. Led by cancer research pioneers, MEKanistic is advancing a novel class of selective kinase inhibitors rationally designed to target both EGFR and PI3K with a single...See details»
Mekanistic Therapeutics, LLC - VentureRadar
MEKanistic Therapeutics is a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK inhibitor field, Judith Sebolt-Leopold, PhD, and Christopher …See details»
Mekanistic Therapeutics LLC - Drug pipelines, Patents, Clinical …
About MEKanistic Therapeutics, Inc. MEKanistic Therapeutics Inc. is a privately held, Minneapolis, MN based biotechnology company focused on developing innovative kinase …See details»
MEKanistic Therapeutics - Products, Competitors, Financials, …
MEKanistic Therapeutics operates as a biotechnology company focusing on developing innovative cancer therapies. Its main product includes a novel class of selective kinase …See details»
MEKanistic Therapeuticsâ„¢ announces the appointment of Dr.
Jun 7, 2023 · Minneapolis, MN - MEKanistic Therapeutics Inc., a biotechnology company redefining the future of kinase inhibitors for the treatment of cancer, announces the addition of …See details»
Invenshure Launches MEKanistic Therapeuticsâ„¢
Jun 2, 2022 · Venture studio Invenshure announces the launch of MEKanistic Therapeutics, a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK …See details»
MEKanistic page — Invenshure
Led by cancer research pioneers, MEKanistic Therapeutics is advancing a novel class of selective kinase inhibitors rationally designed to target both EGFR and PI3K with a single molecule.See details»
Invenshure Launches MEKanistic Therapeuticsâ„¢ - PR Newswire
Jun 2, 2022 · Invenshure launches MEKanistic Therapeutics, redefining precision oncology with a breakthrough drug. MEKanistic will be launching a round of funding in the coming weeks to …See details»
MEKanistic Therapeutics Inc.'s First-in-Class Dual EGFR and PI3K ...
Jul 11, 2024 · MTX-531 is a potential first-in-class therapy uniquely designed to inhibit both EGFR (Epidermal Growth Factor Receptor) and PI3K (Phosphoinositide 3-kinase), two critical …See details»
MEKanistic Therapeutics First-in-Class Cancer Clinical Candidate ...
Aug 1, 2023 · Minneapolis, MN – MEKanistic Therapeutics, a pioneering biotechnology company revolutionizing kinase inhibitors for cancer treatment, announced today that its investigational …See details»
MEKanistic Therapeutics First-in-Class Cancer Clinical Candidate ...
Aug 1, 2023 · MEKanistic Therapeutics is a biotechnology company focused on developing innovative kinase inhibitors for the treatment of cancer. Its lead candidate is a rationally …See details»
MEKanistic Therapeutics Inc.'s First-in-Class Dual EGFR and PI3K ...
Jul 11, 2024 · MEKanistic Therapeutics Inc. is a privately held, Minneapolis, MN based biotechnology company focused on developing innovative kinase inhibitors for the treatment of …See details»
MEKanistic Therapeutics Inc.’s First-In-Class Dual EGFR and PI3K ...
Jul 17, 2024 · MEKanistic Therapeutics Inc. is a privately held, Minneapolis, MN-based biotechnology company focused on developing innovative kinase inhibitors for the treatment of …See details»
A first-in-class selective inhibitor of EGFR and PI3K offers a single ...
Here, we show that MTX-531 acts as a weak agonist of peroxisome proliferator-activated receptor-γ, an attribute that likely mitigates hyperglycemia induced by PI3K inhibition. This …See details»
MEKanistic Therapeutics Inc.'s First-in-Class Dual EGFR and PI3K ...
Jul 11, 2024 · MTX-531 is a potential first-in-class therapy uniquely designed to inhibit both EGFR (Epidermal Growth Factor Receptor) and PI3K (Phosphoinositide 3-kinase), two critical …See details»
Nivolumab in Patients With Advanced or Metastatic Malignancies ...
1 day ago · PURPOSETo report on CheckMate 627 (ClinicalTrials.gov identifier: NCT02832167), a phase II adaptive basket design trial of nivolumab in uncommon advanced/metastatic …See details»